Boehringer Ingelheim International GmbH
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Boehringer Ingelheim International GmbH - overview
Established
1885
Location
-, -, Germany
Primary Industry
Pharmaceuticals
About
Boehringer Ingelheim International GmbH, based in Germany, specializes in developing and manufacturing healthcare solutions for both human and animal health, focusing on innovative pharmaceuticals and animal health products. Founded in 1885, Boehringer Ingelheim operates in the healthcare sector, providing advanced medical solutions aimed at improving patient outcomes. The company's headquarters is located in Ingelheim am Rhein, Germany. Jan van der Merwe is noted as the founder.
The current leadership team includes CEOs Joachim Wenzel, Juan Duran, Mark Benedict, Mark Lewis, Maurizio Sartorato, and Simone Schulz. Boehringer Ingelheim offers a diverse range of healthcare products and services focusing on both human and animal health. The company's primary offerings in human health include innovative pharmaceuticals aimed at treating serious conditions such as heart diseases, cancer, and metabolic disorders. In the realm of animal health, Boehringer Ingelheim is recognized for providing solutions for disease prevention and treatment across various species, ensuring the health and welfare of livestock and companion animals.
Their global market reach spans North America, Europe, Asia, and Latin America, particularly emphasizing emerging markets. In 2021, Boehringer Ingelheim reported a revenue of EUR 14. 0 bn, driven by its Human Pharma and Animal Health divisions. The company's revenue generation model focuses on direct sales to healthcare providers and veterinarians, utilizing B2B channels for medication and vaccine procurement.
Their flagship products, integral to revenue, include therapies for chronic conditions and advanced vaccines, serving a significant clientele worldwide.
Primary Industry
Pharmaceuticals
Sub Industries
Biopharmaceuticals, Pharmaceutical Research & Development
Website
www.boehringer-ingelheim.com/
Verticals
Manufacturing
Total Amount Raised
Subscriber access only
Boehringer Ingelheim International GmbH - timeline of key events
Boehringer Ingelheim International GmbH - financials
| Fiscal Year Ended | Dec 31, 2010 | Dec 31, 2011 | Dec 31, 2012 | Dec 31, 2013 | Dec 31, 2014 | Dec 31, 2015 | Dec 31, 2016 | Dec 31, 2017 | Dec 31, 2018 | Dec 31, 2019 | Dec 31, 2020 | Dec 31, 2021 | Dec 31, 2022 | Dec 31, 2023 | Dec 31, 2024 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue (USD) | 4,945,952,000 | 5,601,454,000 | 6,511,030,000 | 6,148,912,000 | 6,438,696,000 | - | 7,733,656,000 | 6,892,893,000 | 6,993,372,000 | 8,451,363,000 | 8,837,461 | 8,937,839,000 | - | - | - |
| % Revenue Growth (YoY) | - | 13.3% | 16.2% | (5.6%) | 4.7% | - | - | (10.9%) | 1.5% | 20.8% | (99.9%) | 101035.8% | - | - | - |
| EBITDA (USD) | 320,537,000 | 1,196,120,000 | 528,892,000 | 1,207,146,000 | 1,722,966,000 | - | 1,617,569,000 | 2,930,060,000 | 3,774,769,000 | 2,710,346,000 | 3,635,436 | 2,324,649,000 | - | - | - |
| Operating Income (USD) | 303,115,000 | 1,181,277,000 | 515,704,000 | 1,192,603,000 | 1,708,115,000 | - | 1,604,706,000 | 2,913,719,000 | 3,751,342,000 | 2,597,813,000 | 3,503,761 | 2,272,955,000 | - | - | - |
| Operating Margin | 6.1% | 21.1% | 7.9% | 19.4% | 26.5% | - | 20.7% | 42.3% | 53.6% | 30.7% | 39.6% | 25.4% | - | - | - |
| % EBITDA Margin | 6.5% | 21.4% | 8.1% | 19.6% | 26.8% | - | 20.9% | 42.5% | 54.0% | 32.1% | 41.1% | 26.0% | - | - | - |
| NET Income (USD) | (33,000) | 1,098,969,000 | 586,835,000 | 1,259,287,000 | 1,699,310,000 | - | 1,666,178,000 | 2,496,951,000 | 3,645,711,000 | 2,541,371,000 | 3,516,325 | 2,247,613,000 | - | - | - |
| % Net Margin | (0.0%) | 19.6% | 9.0% | 20.5% | 26.4% | - | 21.5% | 36.2% | 52.1% | 30.1% | 39.8% | 25.1% | - | - | - |
Boehringer Ingelheim International GmbH - employee data
Boehringer Ingelheim International GmbH - key contacts
| Name | Position | Start Date | End Date | Vcard | Bio | ||
|---|---|---|---|---|---|---|---|
| Board Member South East Asia | BM |
BM Board Member
Want to see more?
Request a demo for full access to this profile
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.